Stock Report

Download full stock data and analysis for free Last Updated: 07-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Nurix Therapeutics Inc (NRIX) Key Ratios

Stock Card factsheet share-fund-plan-icon

$26.14

up-down-arrow $0.82 (3.24%)

As on 04-Sep-2026 16:00EDT

Market cap

info icon

$2,713 Mln

Revenue (TTM)

info icon

$37 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

6.7

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 44.64 -79.47 -58.40 -15.50 9.95
EBIT -3.02 -110.30 -65.46 -155.39 -212.35
Net Profit -2.71 -106.00 -64.65 -155.20 -212.87
EPS -- -- -- -- --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMNov-25Nov-24
EBIT-Margin info -285.11-345.52-929.18-314.00-354.36
Net Margin info ---388.71-928.44----
Return on equity info -53.32-49.68-72.52-49.63-53.22
Return on Capital info -49.29-46.74---46.00-49.23
Return on Assets info -38.00-35.60-53.56-38.96-37.77
Debt to Equity (x) info ----0.000.100.05

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
--
-46.00
-49.23
-52.65
-49.49
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-72.52

Lower than Peers by 32.19

Profit after tax / Average Net worth * 100

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
-72.52
-49.63
-53.22
-57.10
-51.41
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-53.56

Lower than Peers by 22.31

Profit after tax / Average Total assets * 100

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
-53.56
-38.96
-37.77
-37.27
-37.17
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-929.18

Lower than Peers by 846.58

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
-929.18
-314.00
-354.36
-186.98
-476.01
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-928.44

Lower than Peers by 837.14

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
-928.44
-314.90
-354.85
-186.98
-394.09
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Lower than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-58.40

Lower than Peers by 112.44

Year on year growth in net sales

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
-58.40
0.54
-0.29
0.99
0.30
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-65.46

Lower than Peers by 64.44

Year on year growth in operating profit (EBIT)

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
-65.46
-36.42
-34.28
21.71
-55.97
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-64.65

Lower than Peers by 57.12

Year on year growth in profit after tax

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
-64.65
-36.62
-34.47
13.31
-41.68
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
--
0.10
0.05
0.15
0.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.01

--

(Short term borrowings / Net worth)

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
0.01
0.01
0.02
0.04
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

6.34

Higher than Peers by 0.53

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
6.34
7.02
6.46
3.40
4.51
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

6.34

Higher than Peers by 0.64

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
6.34
--
--
--
4.52
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
--
--
--
--
-12.84
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
--
--
2.75
1.04
2.85
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.06

Lower than Peers by 0.01

Sales / Average Total Assets

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
0.06
0.12
0.11
0.20
0.09
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
--
6.52
7.70
4.51
34.53
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
--
--
--
-2.12
-18.59
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
--
219.83
14.74
11.07
197.93
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
--
--
--
-8.69
-181.99
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Book Value

6.65

Higher than Peers by 1.33

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
6.65
--
--
--
--
Peer Median
5.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-3.35

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
-3.35
2.19
3.14
1.87
1.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

2,713

Higher than Peers by 2,571

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Nov-25
Nov-24
Nov-23
Nov-22
Nurix Therapeutics Inc (NRIX)
2,713
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...